

Subject: Important Update on Movantik®

June 22, 2017

Dear Healthcare professional,

On December 15, 2016, Knight Therapeutics Inc. ("Knight") entered into an exclusive license agreement with AstraZeneca Canada Inc. ("AZ") to obtain commercial rights for Movantik® in Canada. We are pleased to share that we will transition the Distribution and Order-to-Cash activities for Movantik® from AZ to Knight effective July 1, 2017 ("Transition Date").

The physical products will remain identical at this time, including DIN, GTIN/UPC codes and price.

Product Name	DIN	GTIN/UPC
Movantik® 12.5mg Bottle of 30 Tabs	02442167	620641014718
Movantik® 25mg Bottle of 30 Tabs	02442175	620641014732

If you do not currently have a direct account with Knight, please arrange to open account as per below. If you are a current Trading Partner with Knight required actions are as:

Pre-Transition Date

Update your system to purchase these products from Knight effective July 4, 2017 June 29, 2017 - Last day to place orders with AZ June 30, 2017 – Last day AZ will ship Movantik® orders

Post-Transition Date

July 4, 2017 – First day to place orders with Knight

Claims (damages, short ships): Credit to be processed with company which issued the sales invoice Expired Returns - Effective July 4, 2017 Knight will issue credits as per its terms and conditions and all expired products are sent back to: Knight Therapeutics Inc. Returns department, 1375 Newton, Boucherville, Quebec, J4B 5H2

Payment of Knight's invoices by check: Mail to Knight Therapeutics Inc. 3400 De Maisonneuve W., Suite 1055, Montreal QC. H3Z 3B8

To place an order and/or open an account with Knight Therapeutics Inc.:

Opening account: Call Customer Service at 1-888-234-7256 or 450-552-8174

Placing order: Call Customer Service at 1-888-234-7256 or 450-552-8174 or fax order to 1-844-552-8085 or 450-552-8085 or knight@lsu3pl.ca

For EDI orders, please call customer service at 1-888-234-7256 or 450-552-8174.

Should you have any questions, please contact Knight's customer service at knight@lsu3pl.ca or AZ at AZCTradeRelations@astrazeneca.com or 1-888-669-2987.

Sincerely,

Knight Therapeutics Inc.